LY2835219 is an orally-bioavailable dual inhibitor of cyclin-dependent kinase 4 (CDK4) and CDK6 (IC50s = 2 and 10 nM, respectively).{28691,29192,29193} Through this mechanism, it blocks phosphorylation of retinoblastoma protein, resulting in arrest of cell cycling in the G1 phase. LY2835219 has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds.{29192,29193}
产品描述
An orally-bioavailable dual inhibitor of CDK4 and CDK6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
